ER beta inhibits proliferation and invasion of breast cancer cells.

(1)

HAL Id: inserm-00153812

https://www.hal.inserm.fr/inserm-00153812

Submitted on 12 Jun 2007

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of sci-entific research documents, whether they are

pub-L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non,

ER beta inhibits proliferation and invasion of breast

cancer cells.

Gwendal Lazennec, Damien Bresson, Annick Lucas, Corine Chauveau,

Françoise Vignon

To cite this version:

Gwendal Lazennec, Damien Bresson, Annick Lucas, Corine Chauveau, Françoise Vignon. ER beta inhibits proliferation and invasion of breast cancer cells.. Endocrinology, Endocrine Society, 2001, 142 (9), pp.4120-30. �inserm-00153812�

(2)

B

A

E

D

C

F

B

CMV

hER

Ad-hER

pJM17

pAC

SK12-CMV5-hER

CMV

hER

SV40

polyAd

A

Fig. 1

(3)

48 0 1 4 12 24 Ad5

hER

α

48 0 1 4 12 24 Ad5

hER

β

C Ad5

hER

α

hER

β

αAb

βAb

hER

α

hER

β

Ad5

αAb

βAb

A

B

C

1

2

3

4

5

6

Time (h) 1.6 1.0 0.5 kb 84 kDa 62 51 38

(4)

Ad5

Ad-hER

α

Ad-hER

β

α Ab

β Ab

(5)

% of NI Activity

CMV hERα hERβ

C

E2

%

o

f NI Ac

tivity

Ad5

Ad-hERα

Ad-hERβ

A

B

C

E2

0.1 1

10

100

0.1

1

10

100

0 400 800 1200 1600 2000 2400 2800 0 1000 2000 3000 4000

(6)

% of NI Activity

Ad-hERα

Ad-hERβ

[E2]

C

CMV

hERα hERβ

Ad5 Ad-hERα Ad-hERβ

%

o

f NI Ac

tivity

C

E2

ICI

E2 + ICI

D

0 1000 2000 3000 4000 0 -12 -11 -10 -9 -8 -7 0 1000 2000 3000 4000

Fig. 3

(7)

p21

0 1 4 12 24 48 0 1 4 12 24 48 0 1 4 12 24 48

TGF

α

Ad5

Ad-hER

α

Ad-hER

β

pS2

28S

time (h)

c-myc

A

B

p21 0 20 40 60 80 100 120 % of E R α 48h Ad5 ERα ERβ 0 1 4 12 24 48 0 1 4 12 24 48 0 1 4 12 24 48 TGFα 0 20 40 60 80 100 % of E R α 48h Ad5 ERα ERβ 0 1 4 12 24 48 0 1 4 12 24 48 0 1 4 12 24 48 pS2 0 20 40 60 80 100 % of E R α 48h Ad5 ERα ERβ 0 1 4 12 24 48 0 1 4 12 24 48 0 1 4 12 24 48 c-myc 0 20 40 60 80 100 120 % o f A d 5 0h Ad5 ERα ERβ 0 1 4 12 24 48 0 1 4 12 24 48 0 1 4 12 24 48

(8)

C

E

I

EI

C

E

I

EI

C

E

I

EI

pS2

p21

TGF

α

C

TGF

α

0

50

100

150

200 ERα

ERβ

C

E2

ICI

ICI + E2

pS2

0

50

100

150

200

250 ERα

ERβ

p21

0

50

100

150

200

250 ERα

ERβ

Ad5

Ad-hER

α

Ad-hER

β

S c an (a rbitr a ry units) S c an (a rbitr a ry units) S c a n (a rbitr a ry units)

Fig. 4

(9)

NI NI+E2 Ad5+E2 Ad5 25000 45000 65000 85000 105000 125000 145000 165000 185000 0 2 4 6 days Ce ll numb e r Ad5 hERα hERα + E2 Ad5 hERβ hERβ+E2 25000 45000 65000 85000 105000 125000 145000 165000 185000 0 2 4 6 days Ce ll numb e r 25000 45000 65000 85000 105000 125000 145000 165000 185000 0 2 4 6 days Ce ll numb e r